

Special Issue

Metabolic Reprogramming and Immune Modulation in the Tumor Microenvironment: From Mechanisms to Immunotherapy Enhancement

Message from the Guest Editor

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

Cancer cell metabolic reprogramming and TME composition/function;

Tumor-derived metabolites and immunomodulatory effects;

Metabolic competition and nutrient depletion in immune dysfunction;

Hypoxia-driven metabolic plasticity and immunosuppression;

Cancer-associated fibroblast metabolism and immune remodeling;

Metabolic regulation of tumor-infiltrating lymphocytes, regulatory T cells, and myeloid-derived suppressor cells;

Cancer stem cells, metabolic dormancy, and immunotherapy resistance;

Nutrigenomic and epigenetic approaches targeting metabolic enzymes for immune enhancement;

Checkpoint inhibitor resistance mechanisms and metabolic contributions;

Clinical and translational studies bridging metabolic profiling with immunotherapy outcomes.

Guest Editor

Dr. Reza Bayat Mokhtari

1. Association of Clinical Immunology and Cancer Research (ACICR), San Diego, CA 92127, USA
2. California Comprehensive Allergy and Food Institute, P.C., (CalCafi, P.C.), San Diego, CA 92131, USA
3. Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada

Deadline for manuscript submissions

30 June 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/264931

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).